Skip Navigation


European Heart Journal Advance Access originally published online on October 24, 2007
European Heart Journal 2007 28(22):2693-2694; doi:10.1093/eurheartj/ehm474
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/22/2693    most recent
ehm474v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Vlaar, P. J.
Right arrow Articles by Zijlstra, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vlaar, P. J.
Right arrow Articles by Zijlstra, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

DES or BMS in acute myocardial infarction?

Pieter J. Vlaar*, Bart J. G. L. de Smet and Felix Zijlstra

Department of Cardiology, University Medical Centre Groningen Thorax Centre, Groningen, The Netherlands

* Corresponding author. Tel: +31 50 3611413; fax: +31 50 3614391. E-mail address: p.j.j.vlaar@thorax.umcg.nl

This editorial refers to ‘Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction’ by A. Kastrati et al., on page 2706

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

The prognosis of patients with acute myocardial infarction (AMI) has been considerably improved following the introduction of reperfusion therapies. The primary aim in the acute phase of an AMI is rapid and sustained restoration of blood flow through the infarct-related artery. When logistically feasible, primary percutaneous coronary intervention (PCI) has emerged as the preferred reperfusion modality. Compared with balloon angioplasty, implantation of a bare metal stent (BMS) results in a lower rate of reocclusion and restenosis. Nevertheless, rates of target vessel revascularization after BMS implantation in patients with . . . [Full Text of this Article]

Is the external validity of DES vs. BMS trials in acute myocardial infarction compromised?

Late and very late stent thrombosis (>1 or >3 years after implantation)

The clinical outcome of DES after 3–5 years

Cost–benefit ratio of DES

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
Adnan Kastrati, Alban Dibra, Christian Spaulding, Gerrit J. Laarman, Maurizio Menichelli, Marco Valgimigli, Emilio Di Lorenzo, Christoph Kaiser, Ilkka Tierala, Julinda Mehilli, Melchior Seyfarth, Olivier Varenne, Maurits T. Dirksen, Gianfranco Percoco, Attilio Varricchio, Undine Pittl, Mikko Syvänne, Maarten J. Suttorp, Roberto Violini, and Albert Schömig
EHJ 2007 28: 2706-2713. [Abstract] [Full Text]